In the phase 2 WSG-ADAPT-TP study, T-DM1, T-DM1 and hormone therapy, and trastuzumab and hormone therapy were compared in a 12-week neoadjuvant setting in patients with HER2 + , HR–positive early breast cancer [18]. This evidence concerns the gene ERBB2 and breast carcinoma.